Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Yiteng Jihe (6998.HK) announces earnings, Biopharma sets sail
On March 27, the groundbreaking completion of the first reverse acquisition of Hong Kong stock 18A by Yiteng Jiahe (6998.HK) announced its 2025 performance report, with annual sales revenue of 2.49 billion yuan, leading the 2 billion level for three consecutive years; net profit reached 400 million yuan, achieving steady growth; cash and cash equivalents on the balance sheet totaled 1.05 billion yuan, indicating ample funds. The company’s R&D expenditure increased to 6.5%, while sales and distribution expenses further decreased to 24.1%, significantly optimizing the financial rate.
Yiteng Jiahe’s three original research classic products provide the company with highly stable cash flow revenue, while four innovative products have also become strong growth engines. In addition, the company has established a macromolecule antibody drug R&D platform and a small nucleic acid drug R&D platform, continuously delivering innovative results, with 10 existing pipelines under research, including GB268, EDP167, and GB261, which have entered the clinical stage and are all potential best-in-class (BIC) products. The company has considerable sales and cash flow, along with popular target pipelines, maintaining a solid core growth logic.